"Safe" and "effective" are defined as follows: Safety is the condition of presenting a reasonably low risk of harm, injury, or loss when a technology is utilized in the specified indication; and effectiveness is the quality of producing a desired, beneficial effect under the conditions of actual use. The categories for response to a DATTA question are defined as follows: established—a technology demonstrated and accepted as safe and effective by the practicing medical community; investigational—a technology largely confined to use under research protocol; unacceptable—the risk-benefit ratio is unfavorable; and indeterminate—the evidence is insufficient for a definitive decision, and no consensus exists to date; further study may be warranted.
χ2 Analysis of the distribution of panelists' responses for questions 1A, 1B, 2A, and 2B showed that the responses differed significantly from those expected by chance alone (P<.05). Comparison of the 95% confidence interval of the proportion of "investigational" responses to the combined responses of "established," "unacceptable," and "indeterminate" showed a statistically significant majority of the panelists believe the answer should be "investigational" for questions 1A, 1B, 2A, and 2B. Seventeen panelists offered no opinion on question 1A, 16 had no opinion on question 1B, and 15 panelists offered no opinion for questions 2A and 2B.
Continuous subcutaneous insulin infusion . JAMA. 1989;;262:1239-1243.
Rasio E. In vitro permeability of rat mesentery to different molecules with a particular reference to insulin . Arch Int Pharmacodyn Ther. 1967;;167:493-494.
Crossley K, Kjellstrand CM. Intraperitoneal insulin for control of blood sugar in diabetic patients during peritoneal dialysis . Br Med J. 1971;;1:269-270.
Blumenkrantz MJ, Shapiro DJ, Mimura N, et al. Maintenance peritoneal dialysis as an alternative in the patient with diabetes mellitus and end-stage uremia . Kidney Int Suppl. 1974;;1:108-114.
Schade DS, Eaton RP, Spencer W, Goldman R, Corbett WT. The peritoneal absorption of insulin in a diabetic man: a potential site for a mechanical insulin delivery system . Metabolism. 1979;;28:195-197.
Flynn CT, Nanson JA. Intraperitoneal insulin with CAPD—an artificial pancreas . Trans Am Soc Artif Intern Organs. 1979;;25:114-117.
Schade DS, Eaton RP. The peritoneum—a potential insulin delivery route for a mechanical pancreas . Diabetes Care. 1980;;3:229-234.
Irsigler K, Kritz H. Alternate routes of insulin delivery . Diabetes Care. 1980;;3:219-228.
Marshall SM, Husband DJ, Walford S, Wright PO, Alberti KGMM. Use of intraperitoneal insulin in brittle diabetes . Diabetologia. 1983;;25:179.
Selam JL, Slingeneyer A, Saeidi S, Mirouze J, Richard JL, Rodier M. Experience with long-term peritoneal insulin infusion with external pumps . Diabetic Med. 1985;;2:41-44.
Kritz H, Najemnik C, Hagmueller G, et al. Long-term results using different routes of insulin infusion . In: Irsigler K, Kritz H, Lovett R, eds. Diabetes Treatment With Implantable Insulin Infusion Systems . Munich, Germany: Urban & Schwarzenberg; 1983;:81-102.
Selam JL, Giraud P, Mirouze J, et al. Continuous peritoneal insulin infusion with portable pumps: factors affecting the operating life of the chronic catheter . Diabetes Care. 1985;;8:34-38.
Eaton RP, Schade DS, Pitcher L. Catheter encapsulation during prolonged intraperitoneal insulin infusion in a patient implanted with a remote controlled insulin delivery system . In: Irsigler K, Kritz H, Lovett R, eds. Diabetes Treatment With Implantable Insulin Infusion System . Munich, Germany: Urban & Schwarzenberg; 1983;:126-130.
Popovich RP, Moncreif JW, Nolph KD, Ghods AJ, Twardowski ZJ, Pyle WK. Continuous ambulatory peritoneal dialysis . Ann Intern Med. 1978;;88:449-456.
Schade DS, Eaton RP. Intraperitoneal insulin delivery . In: Brunetti P, ed. Artificial Systems for Insulin Delivery . New York, NY: Raven Press; 1983;:161-166.
Albisser AM, Leibel BS, Ewart TG, et al. An artificial endocrine pancreas . Diabetes. 1974;;23:389-396.
Schade DS, Santiago JV, Skyler JS, Rizza RA. Intensive Insulin Therapy . Amsterdam, the Netherlands: Medical Examination Publishing Co Inc; 1983;.
Williamson JR, Bahoric A, Perlman K, Albisser AM. Secondary amyloidosis in (beagle) dogs receiving intravenous insulin via mechanical pumps . Diabetes. 1982;;31(
Pickup JC. Amyloid and insulin infusion pumps . Diabetic Med. 1985;;2:13-16.
Schade DS, Eaton RP, Spencer W. Implantation of an artificial pancreas: current perspectives . JAMA. 1981;;245:709-710.
Brange J, Havelund S. Insulin pumps and insulin quality—requirements and problems . Acta Med Scand Suppl. 1983;;671:135-138.
Blackshear PJ, Rohde TD, Palmer JL, et al. Glycerol prevents insulin precipitation and interruption of flow in an implantable insulin infusion pump . Diabetes Care. 1983;;6:387-392.
Grau U, Saudek CD. Stable insulin preparation for implanted insulin pumps: laboratory and animal trials . Diabetes. 1987;;36:1453-1459.
Investigator's Brochures for HOE 21 PH Insulin, U100 and U400 . Somerville, NJ: Hoechst-Roussel Pharmaceuticals Inc;
Saudek CD. Implantable insulin infusion pumps: a case presentation . Diabetes Educ. 1989;;15:44-49.
Buchwald H, Rohde TD. Implantable Pumps: ASAIO Primers in Artificial Organs . Hagerstown, Md: JB Lippincott; 1987;.
Rupp WM, Barbosa JJ, Blacksheer PJ, et al. The use of an implantable insulin pump in the treatment of type II diabetes . N Engl J Med. 1982;;307:265-270.
Buchwald H, Chute WM, Rupp JJ, et al. Implantable infusion pump for insulin delivery: past, present, and future . J Eur Soc Artif Organs. 1985;;3:51-53.
Blackshear PJ, Roussell AM, Cohen AM, Nathan DM. Basal-rate intravenous insulin infusion compared to conventional insulin treatment in patients with type II diabetes . Diabetes Care. 1989;;12:455-463.
Irsigler K, Kritz H, Hagmüller G, et al. Long-term continuous intraperitoneal insulin infusion with an implanted remote-controlled insulin infusion device . Diabetes. 1981;;30:1072-1075.
Schade DS, Eaton P, Edwards WS, et al. A remotely programmable insulin delivery system: successful short-term implantation in man . JAMA. 1982;;247:1848-1853.
Selam JL. Development of implantable insulin pumps: long is the road . Diabetic Med. 1988;;5:624-633.
Saudek CD, Selam JL, Pitt HA, et al. A preliminary trial of the programmable implantable medication system for insulin delivery . N Engl J Med. 1989;;321:574-579.
Knatterud GL, Fisher M for the ISGIID Investigators. International Study Group on Implantable Insulin Delivery Devices Registry . Diabetes Nutr Metab. 1988;;1:323-328.